Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects

Deleterious variants in the BRCA1/BRCA2 genes and homologous recombination deficiency (HRD) status are considered strong predictors of response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). The introduction of PARPi in clinical practice for the treatment of patients with advanced ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Peixoto, Ana, Pinto, Pedro, Guerra, Joana, Pinheiro, Manuela, Santos, Catarina, Pinto, Carla, Santos, Rui, Escudeiro, Carla, Bartosch, Carla, Canário, Rita, Barbosa, Ana, Gouveia, Alfredo, Petiz, Almerinda, Abreu, Miguel Henriques, Sousa, Susana, Pereira, Deolinda, Silva, João, Teixeira, Manuel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412538/
https://www.ncbi.nlm.nih.gov/pubmed/32850417
http://dx.doi.org/10.3389/fonc.2020.01318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412538/
https://www.ncbi.nlm.nih.gov/pubmed/32850417
http://dx.doi.org/10.3389/fonc.2020.01318

Ejemplares similares